

THE UNIVERSITY OF MICHIGAN  
REGENTS COMMUNICATION

ACTION REQUEST

Subject: Research Agreement between the University of Michigan and IFM Therapeutics, Inc.

Action Requested: Authorization to enter into Agreement

Preamble:

A statutory conflict of interest situation was identified by the Office of Research and Sponsored Projects while reviewing the Proposal Approval Form which then triggered a review by the Medical School Conflict of Interest Board and the UMOR Conflict of Interest Review Committee. A plan for management of the possible risks associated with the conflict of interest was then developed and approved by the Board and Committee and agreed to by the parties involved.

This proposed research agreement ("Agreement") falls under the State of Michigan Conflict of Interest Statute because Professors Anthony Oipari, Jr., Luigi Franchi, and Gary Glick are employees of the University of Michigan ("University"), and partial owners of IFM Therapeutics, Inc. The law permits such an Agreement provided it is disclosed to the Board of Regents ("Regents") of the University of Michigan and approved in advance by a 2/3 vote.

Background:

Anthony Oipari, Jr., MD, PhD, an Associate Professor in the Department of Obstetrics and Gynecology, Luigi Franchi, MD, an Assistant Professor in the Department of Pediatrics, Gary Glick, MD, a Professor in the Department of Chemistry, are partial owners of IFM Therapeutics, Inc. (the "Company"). The Company wishes to provide additional funding for a project entitled: "Mechanistic Studies of MLRP1 Protein Function" (ORSP# 17-PAF01790) in the Department of Obstetrics and Gynecology, under the direction of Dr. Anthony Oipari, Jr. The purpose of this project is to develop and test mechanistic hypotheses that advance understanding of the role and regulation of NLRP1 protein in immune diseases and cancer.

Agreement Terms:

The terms of the Agreement conform to University policy. The period of performance for the project is approximately six (6) months. The additional amount of funding shall not exceed \$96,687. Since research projects are often amended, this agreement includes provisions for changes in time and scope. University procedures for approval of these changes will be followed and additional conflict of interest review will be done as appropriate.


Impact of the Agreement

The Agreement will support an effort by Dr. Opipari, Jr. to use his expertise and University laboratory, as well as other University resources, to support the University's participation in the research project.

Recommendations:

This matter has been reviewed and approved by the Medical School Conflict of Interest Board and the UMOR Conflict of Interest Review Committee. In light of this disclosure and our finding that the Agreement was negotiated in conformance with standard University practices, I recommend that the Board of Regents approve the University's entering into this Agreement with IFM Therapeutics, Inc.

Respectfully submitted,



S. Jack Hu  
Vice President for Research

October 2016